Product Reports Resources Pricing Login Book a demo

Synoste

Health Tech & Medtech · Espoo, Finland · Founded 2012

Develops treatment solutions for skeletal deformities MoreLess

Synoste Oy was a Finnish medical technology company that developed solutions for skeletal deformities, focusing on a less invasive and more patient-friendly approach to limb lengthening. The company was established in 2012 as a spin-off from Aalto University by co-founders Harri Hallila, Juha Haaja, and Antti Ritvanen. Their shared background in bioadaptive technology at the university, with research beginning in 2007, formed the foundation of the company's technology.

The company's core product was the Synoste Nitinail, a telescopic intramedullary nail designed to be implanted into the bone. This system utilized smart materials, specifically a nickel-titanium shape memory alloy, which would expand with precision when gently heated. The heating process was managed by the patient at home using a wireless, external device that transferred energy to the implant via electromagnetic induction. This process, performed for short durations daily, would gradually lengthen the bone by up to 7 centimeters. The approach was developed to reduce the high rates of pain, infection, and other complications associated with traditional external fixators. The technology platform was also envisioned to extend to other applications, including spinal and craniomaxillofacial corrections.

Synoste's business model revolved around the development and future sale of these medical devices to the global orthopedic market. Throughout its operation as an independent startup, the company secured significant funding to advance its product from prototype to clinical trials. It raised a total of $11 million over six funding rounds from a syndicate of investors including High-Tech Gründerfonds, Lifeline Ventures, Evonik Venture Capital, AO Invest, and Finnvera. In October 2020, Synoste was acquired by Globus Medical, a U.S.-based musculoskeletal solutions company, for $23.5 million. Following the acquisition, co-founder Harri Hallila, who had served as CEO, transitioned to a role at Globus Medical to continue overseeing the technology's development.

Keywords: limb lengthening, skeletal deformities, orthopedic implants, intramedullary nail, shape memory alloy, medical device, patient-friendly treatment, Globus Medical, Harri Hallila, Juha Haaja, Antti Ritvanen, Aalto University spin-off, minimally invasive surgery, bone correction, smart materials, orthopedic technology, medtech, Nitinail, homecare device, skeletal correction

Talent graph

Synoste's talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Synoste's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 11 investors entered at this stage
Joose Viljanen
Frontier Middle East FZ-LLC,
Pekka Koskinen
Lifeline Ventures
HTGF
Finnvera
Tekes
Metsola Ventures
Innovestor
Petri Pöyhönen
Mectalent
Series B+ 2 investors entered at this stage
Evonik Venture Capital
XR Invest

Global footprint

Where Synoste has talent and traffic

Workforce by country
1 countries with
team presence
🇫🇮 Finland100%
1 country shown

Market sentiment

What the market is saying about Synoste

An AI-synthesized read of the highest-engagement posts about Synoste on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synoste on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.